Radiation & immune drug combo aims to shrink tumors before surgery
NCT ID NCT07371234
Summary
This study is testing a two-part treatment given before surgery for advanced head and neck cancer. Patients receive low-dose radiation combined with an immunotherapy drug (an anti-PD-1 inhibitor) to try to shrink the tumor. The goal is to see if this approach makes surgery more effective and improves long-term outcomes for the 22 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Fifth Affiliated Hospital,Sun Yat-sen University
RECRUITINGGuangdong, China
Conditions
Explore the condition pages connected to this study.